Biopharma Quarterly Dealmaking Statistics, Q2 2019
A Look At Financing, M&A And Alliance Activity April-June 2019
Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.